Company intelligence / Profile preview
Yingli Pharma
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Linperlisib, a PI3Kδ inhibitor, is approved in China for relapsed follicular lymphoma and is entering a global Phase 3 trial for T-cell lymphoma. Phase 2 data showed clinically meaningful efficacy in relapsed/refractory PTCL, leading to FDA clearance for pivotal trial. Several small-molecule inhibitors targeting RAS, TGFβR1, URAT1, and HIPK2 are in clinical development for solid tumors, hematologic malignancies, and metabolic indications
- Therapeutic areas
- EndocrinologyRheumatologyHematologyOtherOncology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Jiangsu Hengrui Pharmaceuticals (Greater China rights for Linperlisib)
Beyond the preview
Go deeper on Yingli Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yingli Pharma.